» Articles » PMID: 36828379

T1-Weighted Contrast Enhancement, Apparent Diffusion Coefficient, and Cerebral-Blood-Volume Changes After Glioblastoma Resection: MRI Within 48 Hours Vs. Beyond 48 Hours

Overview
Journal Tomography
Publisher MDPI
Specialty Radiology
Date 2023 Feb 24
PMID 36828379
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of the study is to identify the advantages, if any, of post-operative MRIs performed at 48 h compared to MRIs performed after 48 h in glioblastoma surgery.

Materials And Methods: To assess the presence of a residual tumor, the T1-weighted Contrast Enhancement (CE), Apparent Diffusion Coefficient (ADC), and Cerebral Blood Volume (rCBV) in the proximity of the surgical cavity were considered. The rCBV ratio was calculated by comparing the rCBV with the contralateral normal white matter. After the blind image examinations by the two radiologists, the patients were divided into two groups according to time window after surgery: ≤48 h (group 1) and >48 h (group 2).

Results: A total of 145 patients were enrolled; at the 6-month follow-up MRI, disease recurrence was 89.9% (125/139), with a mean patient survival of 8.5 months (SD 7.8). The mean ADC and rCBV ratio values presented statistical differences between the two groups ( < 0.05). Of these 40 patients in whom an ADC value was not obtained, the rCBV values could not be calculated in 52.5% (21/40) due to artifacts ( < 0.05).

Conclusion: The study showed differences in CE, rCBV, and ADC values between the groups of patients undergoing MRIs before and after 48 h. An MRI performed within 48 h may increase the ability of detecting GBM by the perfusion technique with the calculation of the rCBV ratio.

Citing Articles

Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration.

Sanvito F, Kaufmann T, Cloughesy T, Wen P, Ellingson B Front Radiol. 2023; 3:1267615.

PMID: 38152383 PMC: 10751345. DOI: 10.3389/fradi.2023.1267615.


Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay.

Martucci M, Russo R, Giordano C, Schiarelli C, DApolito G, Tuzza L Cancers (Basel). 2023; 15(15).

PMID: 37568606 PMC: 10417432. DOI: 10.3390/cancers15153790.

References
1.
Garcia-Ruiz A, Naval-Baudin P, Ligero M, Pons-Escoda A, Bruna J, Plans G . Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma. Sci Rep. 2021; 11(1):695. PMC: 7804103. DOI: 10.1038/s41598-020-79829-3. View

2.
Sato N, Bronen R, Sze G, Kawamura Y, Coughlin W, Putman C . Postoperative changes in the brain: MR imaging findings in patients without neoplasms. Radiology. 1997; 204(3):839-46. DOI: 10.1148/radiology.204.3.9280269. View

3.
Booth T, Luis A, Brazil L, Thompson G, Daniel R, Shuaib H . Glioblastoma post-operative imaging in neuro-oncology: current UK practice (GIN CUP study). Eur Radiol. 2020; 31(5):2933-2943. PMC: 8043861. DOI: 10.1007/s00330-020-07387-3. View

4.
Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

5.
Aprile I, Armadori M, Conti G, Ottaviano I, Ranaldi A, Ottaviano P . MR Perfusion Imaging of Intracranial Tumors. A Retrospective Study of 218 Patients. Neuroradiol J. 2013; 21(4):472-89. DOI: 10.1177/197140090802100403. View